|Traded as||NASDAQ: TSRO|
Russell 1000 Component
|Founded||2010 in Waltham, Massachusetts|
Number of employees
Tesaro was founded in 2010. The company's first commercial product, Varubi, was approved by the FDA in October 2015. As of 2016, the company had 286 full-time employees, 59 of whom had a PhD or MD. The company's product Niraparib was granted priority review and was given a target action date of June 2017 by the FDA. In March 2017, Tesaro won approval for its drug Zejula to treat ovarian cancer. On May 31, 2017, it was reported that Tesaro Inc. was exploring a sale.
Products under development
- Rolapitant – intravenous form in phase III clinical trials for use in chemotherapy-induced nausea and vomiting
- Niraparib – PARP inhibitor in clinical trials for breast and ovarian cancer.
- "Tesaro". FierceBiotech. Retrieved 2017-02-25.
- "TESARO - Quarterly Report". Ir.tesarobio.com. Retrieved 2017-02-25.
- "TESARO - Annual Report". Ir.tesarobio.com. Retrieved 2017-02-25.
- ESARO (TSRO) Announces Priority FDA Review for Niraparib NDA, Street Insider, December 20, 2016, Archived from the original on December 21, 2016, retrieved June 8, 2017CS1 maint: BOT: original-url status unknown (link)
- D. Rockoff, Jonathan; Cimilluca, Dana (May 31, 2017). "Tesaro Explores Sale". Wall Street Journal. New York City, New York. Retrieved June 1, 2017.
- "2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial". ESMO. Retrieved 2017-02-25.